- Sathgen Therapeutics completes dosing of first two cohorts of healthy volunteers with MSP008-22, a new antiviral drug
MSP008-22 is a new drug candidate that shows excellent efficacy against various viruses during its preclinical development.
MUMBAI, India, Aug. 16, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of India's leading chemical conglomerate - Godavari Biorefineries Limited (GBL), announced that it has completed dosing of the first two cohorts of healthy volunteers in a phase 1 clinical trial for MSP008-22, its new chemical entity (NCE). The clinical trial program is managed by Clinexel Life Sciences, a leading clinical research organization in the pharmaceutical industry.
Sathgen is a new clinical-stage therapeutics company focused on developing therapies for difficult-to-treat conditions such as viral infections. Its main molecule, MSP008-22, has broad antiviral potential due to its ability to inhibit both virus entry and replication. This NCE has demonstrated exceptional efficacy and safety against COVID-19 in preclinical development.
Dr. Sangeeta Srivastava, CEO of GBL and CSO of Sathgen Therapeutics, underscored the importance of tackling viral pandemics that have historically caused immense loss of life and hampered economic growth. "We are very pleased that our first program with MSP008-22 is entering the phase of clinical safety testing, with the potential to treat viral infections," she stated.
Professor Sendurai Mani, Associate Director of the Legorreta Cancer Center at Brown University and Co-Founder of Sathgen Therapeutics, explained: "Viral diseases with the potential to cause pandemics have limited treatment options. MSP008-22 promises to address the enormous unmet need treatment of numerous diseases caused by viruses".
Samir Somaiya, President and MD of GBL; and co-founder of Sathgen Therapeutics, highlighted the company's commitment to research and its goal of discovering therapies for viral diseases. "The MSP008-22 clinical trial will mark an important milestone in our efforts to help patients with viral diseases," he added.
Dr Deepa Arora, CEO of Clinexel, emphasized: "The successful completion of the first two cohorts of this study (NCT05532293) in healthy volunteers without any serious adverse events indicates the safe profile of MSP008-22. We are working to provide drugs that fight the viruses that are plaguing the world today".
Sathgen Therapeutics is focused on developing and commercializing new medicines for diseases with unmet needs. In addition to viral infections, Sathgen remains committed to advancing cancer therapeutics with its lead molecule, MSP008-22, moving toward phase 1b clinical trials for efficacy. For more information, visit the website https://sathgentherapeutics.com.
For collaboration or investment opportunities, please contact Sathgen Therapeutics at BD@sathgentherapeutics.com or Investor.Relations@sathgentherapeutics.c.... For more information visit www.clinicaltrials.gov.
Photo: https://mma.prnewswire.com/media/2182271...Logo: https://mma.prnewswire.com/media/2157753...
View original content: https://www.prnewswire.com/news-releases/sathgen-therapeutics-completa-la-dosificacion-de-las-dos-primeras-cohortes-con-msp008-22-301902061.html